thalidomide and Benign Neoplasms, Brain studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

Excerpt	Relevance	Reference
"Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma."	9.20	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015)
"The Radiation Therapy Oncology Group (RTOG) initiated the single-arm, phase II study 9806 to determine the safety and efficacy of daily thalidomide with radiation therapy in patients with newly diagnosed glioblastoma."	9.17	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). ( Alexander, BM; Curran, WJ; Donahue, BA; Fine, HA; Hartford, AC; Kerlin, KJ; Mehta, MP; Richards, RS; Tremont, IW; Wang, M; Yung, WK, 2013)
"Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)."	9.16	A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012)
"To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy."	9.14	A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. ( Barron, L; Batchelor, TT; Black, PM; Ciampa, A; David, K; Doherty, L; Drappatz, J; Kesari, S; Lafrankie, DC; Norden, A; Ostrowsky, L; Ramakrishna, N; Sceppa, C; Schiff, D; Smith, ST; Weiss, S; Wen, PY; Wong, ET; Zimmerman, J, 2009)
"There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases."	9.13	A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008)
"We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma."	9.13	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008)
"This phase II study aimed at determining the efficacy and safety of irinotecan combined with thalidomide in adults with recurrent glioblastoma multiforme (GBM) not taking enzyme-inducing anticonvulsants (EIACs)."	9.13	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. ( Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK, 2008)
"The combination of temozolomide (TMZ) and thalidomide was reported to produce a high response rate, including shrinkage of brain metastases, in patients with metastatic melanoma."	9.13	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008)
"Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)."	9.12	A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007)
"Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen."	9.12	Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006)
"Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years)."	9.11	Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005)
"The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas."	9.10	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003)
"The combination of temozolomide plus thalidomide seems to be a promising and well-tolerated oral regimen for metastatic melanoma that merits further study."	9.10	Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003)
"To assess response of recurrent malignant gliomas to thalidomide."	9.09	Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001)
"The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma."	7.73	Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006)
"We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow."	7.71	Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001)
"Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods."	7.70	Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. ( Cha, S; Glass, J; Gruber, ML; Johnson, G; Knopp, EA; Litt, A; Lu, S; Zagzag, D, 2000)
"Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)."	6.71	Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004)
"Thalidomide is a well-tolerated drug that may have some activity in the treatment of recurrent glioblastoma."	6.70	Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. ( Bell, DR; Biggs, M; Boyle, FM; Cook, R; Levi, JA; Little, N; Marx, GM; McCowatt, S; Pavlakis, N; Wheeler, HR, 2001)
"Intracerebral plasmacytoma is an extremely rare disease for which no treatment protocol has been established."	5.46	Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. ( Kang, SH; Kim, TS; Ko, SJ; Park, KJ, 2017)
"Thalidomide is considered to be a potent antiangiogenic and immunomodulatory drug for cancer therapy."	5.35	The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. ( Mei, SC; Wu, RT, 2008)
"Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies."	5.33	Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006)
"Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma."	5.20	Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. ( Aldape, KD; Chang, EL; Colman, H; Conrad, CA; De Groot, JF; Fisch, MJ; Floyd, JD; Giglio, P; Gilbert, MR; Gonzalez, J; Groves, MD; Hess, KR; Hsu, SH; Lagrone, LW; Levin, VA; Loghin, ME; Mahajan, A; Penas-Prado, M; Puduvalli, VK; Salacz, ME; Volas-Redd, G; Woo, SY; Yung, WK, 2015)
"The Radiation Therapy Oncology Group (RTOG) initiated the single-arm, phase II study 9806 to determine the safety and efficacy of daily thalidomide with radiation therapy in patients with newly diagnosed glioblastoma."	5.17	A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). ( Alexander, BM; Curran, WJ; Donahue, BA; Fine, HA; Hartford, AC; Kerlin, KJ; Mehta, MP; Richards, RS; Tremont, IW; Wang, M; Yung, WK, 2013)
"Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)."	5.16	A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012)
"To define the maximum tolerated dose (MTD) of lenalidomide, an analogue of thalidomide with enhanced immunomodulatory and antiangiogenic properties and a more favorable toxicity profile, in patients with newly diagnosed glioblastoma multiforme (GBM) when given concurrently with radiotherapy."	5.14	A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. ( Barron, L; Batchelor, TT; Black, PM; Ciampa, A; David, K; Doherty, L; Drappatz, J; Kesari, S; Lafrankie, DC; Norden, A; Ostrowsky, L; Ramakrishna, N; Sceppa, C; Schiff, D; Smith, ST; Weiss, S; Wen, PY; Wong, ET; Zimmerman, J, 2009)
"The combination of temozolomide (TMZ) and thalidomide was reported to produce a high response rate, including shrinkage of brain metastases, in patients with metastatic melanoma."	5.13	Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. ( Agarwala, S; Atkins, MB; Clark, JI; Curti, B; Dutcher, JP; Ernstoff, MS; Lawson, D; Logan, T; Margolin, KA; Sosman, JA; Weiss, G, 2008)
"This phase II study aimed at determining the efficacy and safety of irinotecan combined with thalidomide in adults with recurrent glioblastoma multiforme (GBM) not taking enzyme-inducing anticonvulsants (EIACs)."	5.13	Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. ( Colman, H; Conrad, CA; de Groot, JF; Giglio, P; Gilbert, MR; Groves, MD; Hess, KR; Hsu, SH; Ictech, SE; Jackson, EF; Levin, VA; Mahankali, S; Puduvalli, VK; Ritterhouse, MG; Yung, WK, 2008)
"We conducted a phase II study of the combination of temozolomide and angiogenesis inhibitors for treating adult patients with newly diagnosed glioblastoma."	5.13	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. ( Batchelor, TT; Black, PM; Ciampa, A; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Henson, JW; Kesari, S; Kieran, M; Laforme, A; Ligon, KL; Longtine, JA; Muzikansky, A; Ramakrishna, N; Schiff, D; Weaver, S; Wen, PY, 2008)
"There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases."	5.13	A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008)
"Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen."	5.12	Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006)
"Laboratory and clinical data suggest that the anti-angiogenic agent, thalidomide, if combined with cytotoxic agents, may be effective against recurrent glioblastoma multiforme (GBM)."	5.12	A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. ( Abrey, LE; Chang, SM; Cloughesy, TF; Conrad, CA; DeAngelis, LM; Gilbert, MR; Greenberg, H; Groves, MD; Hess, KR; Lamborn, KR; Liu, TJ; Peterson, P; Prados, MD; Puduvalli, VK; Schiff, D; Tremont-Lukats, IW; Wen, PY; Yung, WK, 2007)
"Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years)."	5.11	Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005)
"The combination of temozolomide plus thalidomide seems to be a promising and well-tolerated oral regimen for metastatic melanoma that merits further study."	5.10	Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. ( Chapman, PB; Foster, T; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Quinn, CJ; Williams, LJ; Wolchok, JD, 2003)
"The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas."	5.10	Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003)
"To assess response of recurrent malignant gliomas to thalidomide."	5.09	Thalidomide as an anti-angiogenic agent in relapsed gliomas. ( Brada, M; Dowe, A; Gore, M; Hines, F; Short, SC; Traish, D, 2001)
"The chemotherapeutic agent temozolomide (TMZ) and the anti-angiogenic agent thalidomide (THD) have both demonstrated anti-tumor activity in patients with recurrent malignant glioma."	3.73	Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Jeon, HJ; Kim, H; Kim, JH; Kim, JS; Kim, JT; Kim, MH; Kim, YJ; Lee, DS; Nam, DH; Park, SY; Shin, T; Son, MJ; Song, HS, 2006)
"We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow."	3.71	Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001)
"Serial MR imaging was performed in 18 consecutive patients with recurrent malignant gliomas receiving both thalidomide and carboplatin for 12-month periods."	3.70	Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. ( Cha, S; Glass, J; Gruber, ML; Johnson, G; Knopp, EA; Litt, A; Lu, S; Zagzag, D, 2000)
" Pharmacokinetic data suggested a decreased metabolism of irinotecan into SN-38 and SN-38-glucuronide when it was administered with thalidomide."	2.72	Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ( Allegrini, G; Amatori, F; Bocci, G; Cerri, E; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Marcucci, L; Masi, G, 2006)
"Temozolomide was administered starting the first day of RT at 150 mg/m(2) daily for 5 days every 4 weeks for the first cycle and escalated to a maximum dose of 200 mg/m(2)."	2.71	Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. ( Chang, SM; Lamborn, KR; Larson, D; Malec, M; Nicholas, MK; Page, M; Prados, MD; Rabbitt, J; Sneed, P; Wara, W, 2004)
"Thalidomide is a well-tolerated drug that may have some activity in the treatment of recurrent glioblastoma."	2.70	Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. ( Bell, DR; Biggs, M; Boyle, FM; Cook, R; Levi, JA; Little, N; Marx, GM; McCowatt, S; Pavlakis, N; Wheeler, HR, 2001)
"The incidence of brain metastases from breast cancer is increasing with diagnosis and therapeutics progress, especially with systemic therapies."	2.50	[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. ( Cao, KI; Kirova, YM, 2014)
"Pomalidomide exposure was not associated with higher probabilities of treatment-emergent adverse events or pomalidomide dose interruptions during Cycle 1."	1.62	Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. ( Benettaib, B; Kassir, N; Li, Y; Ogasawara, K; Palmisano, M; Wang, X; Zhou, S, 2021)
"Intracerebral plasmacytoma is an extremely rare disease for which no treatment protocol has been established."	1.46	Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. ( Kang, SH; Kim, TS; Ko, SJ; Park, KJ, 2017)
"Thalidomide is considered to be a potent antiangiogenic and immunomodulatory drug for cancer therapy."	1.35	The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. ( Mei, SC; Wu, RT, 2008)
"Infantile or capillary hemangioma is the most common vascular tumor of childhood."	1.35	Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. ( Frei-Jones, M; Leonard, JR; McKinstry, RC; Park, TS; Perry, A; Rubin, JB, 2008)
"Chemotherapy for the treatment of brain metastases arising from non-small cell lung cancer (NSCLC) has been limited by poor efficacy and high toxicity."	1.33	[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. ( Hada, M; Horiuchi, T, 2005)
"Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies."	1.33	Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006)
"Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects."	1.33	Thalidomide neuropathy in childhood. ( Chaitow, J; Darras, BT; Fleming, FJ; Jones, HR; Ryan, MM; Vytopil, M, 2005)

Research

Studies (56)

Authors

Clinical Trials (6)

Trial Overview

Trial Outcomes

Median Overall Survival (OS) Comparison of Celecoxib Arms Versus no Celecoxib Arms

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (1.79)	18.7374
1990's	1 (1.79)	18.2507
2000's	35 (62.50)	29.6817
2010's	18 (32.14)	24.3611
2020's	1 (1.79)	2.80

Authors	Studies
Ogasawara, K	1
Kassir, N	1
Wang, X	1
Benettaib, B	1
Zhou, S	1
Palmisano, M	1
Li, Y	1
Kim, TS	1
Ko, SJ	1
Park, KJ	1
Kang, SH	1
Guo, G	1
Gong, K	1
Puliyappadamba, VT	1
Panchani, N	1
Pan, E	1
Mukherjee, B	1
Damanwalla, Z	1
Bharia, S	1
Hatanpaa, KJ	1
Gerber, DE	1
Mickey, BE	1
Patel, TR	1
Sarkaria, JN	1
Zhao, D	1
Burma, S	1
Habib, AA	1
Hauser, P	1
Vancsó, I	1
Pócza, T	1
Schuler, D	1
Garami, M	1
Yung, R	1
Seyfoddin, V	1
Guise, C	1
Tijono, S	1
McGregor, A	1
Connor, B	1
Ching, LM	1
Cao, KI	1
Kirova, YM	1
Devoe, CE	1
Li, JY	1
Demopoulos, AM	1
Penas-Prado, M	1
Hess, KR	4
Fisch, MJ	1
Lagrone, LW	1
Groves, MD	4
Levin, VA	3
De Groot, JF	2
Puduvalli, VK	4
Colman, H	3
Volas-Redd, G	1
Giglio, P	3
Conrad, CA	4
Salacz, ME	1
Floyd, JD	1
Loghin, ME	1
Hsu, SH	2
Gonzalez, J	1
Chang, EL	1
Woo, SY	1
Mahajan, A	1
Aldape, KD	1
Yung, WK	6
Gilbert, MR	4
Iwamoto, FM	1
Lassman, AB	1
Lee, J	1
Smith, D	1
Rabin, N	1
Tobias, J	1
Yong, K	1
Milanovic, D	1
Sticht, C	1
Röhrich, M	1
Maier, P	1
Grosu, AL	1
Herskind, C	1
Martínez-Aranda, A	1
Hernández, V	1
Guney, E	1
Muixí, L	1
Foj, R	1
Baixeras, N	1
Cuadras, D	1
Moreno, V	1
Urruticoechea, A	1
Gil, M	1
Oliva, B	1
Moreno, F	1
González-Suarez, E	1
Vidal, N	1
Andreu, X	1
Seguí, MA	1
Ballester, R	1
Castella, E	1
Sierra, A	1
Shimizu, T	1
Kurozumi, K	2
Ishida, J	1
Ichikawa, T	2
Date, I	2
Simon, AJ	1
Lev, A	1
Zhang, Y	1
Weiss, B	1
Rylova, A	1
Eyal, E	1
Kol, N	1
Barel, O	1
Cesarkas, K	1
Soudack, M	1
Greenberg-Kushnir, N	1
Rhodes, M	1
Wiest, DL	1
Schiby, G	1
Barshack, I	1
Katz, S	1
Pras, E	1
Poran, H	1
Reznik-Wolf, H	1
Ribakovsky, E	1
Simon, C	1
Hazou, W	1
Sidi, Y	1
Lahad, A	1
Katzir, H	1
Sagie, S	1
Aqeilan, HA	1
Glousker, G	1
Amariglio, N	1
Tzfati, Y	1
Selig, S	1
Rechavi, G	1
Somech, R	1
Drappatz, J	3
Wong, ET	1
Schiff, D	4
Kesari, S	3
Batchelor, TT	3
Doherty, L	3
Lafrankie, DC	1
Ramakrishna, N	3
Weiss, S	1
Smith, ST	1
Ciampa, A	2
Zimmerman, J	1
Ostrowsky, L	1
David, K	1
Norden, A	1
Barron, L	1
Sceppa, C	1
Black, PM	3
Wen, PY	5
Vestermark, LW	1
Larsen, S	1
Lindeløv, B	1
Bastholt, L	1
Frei-Jones, M	1
McKinstry, RC	1
Perry, A	1
Leonard, JR	1
Park, TS	1
Rubin, JB	1
Mei, SC	1
Wu, RT	1
Atkins, MB	1
Sosman, JA	1
Agarwala, S	1
Logan, T	1
Clark, JI	1
Ernstoff, MS	1
Lawson, D	1
Dutcher, JP	1
Weiss, G	1
Curti, B	1
Margolin, KA	1
Rüegg, C	1
Peters, S	1
Labro, H	1
Al-Kadhimi, Z	1
Djmil, M	1
Oghlakian, R	1
Alshekhlee, A	1
Aguilera, DG	1
Tomita, T	1
Rajaram, V	1
Fangusaro, J	1
Katz, BZ	1
Shulman, S	1
Goldman, S	1
Sumrall, A	1
Fredericks, R	1
Berthold, A	1
Shumaker, G	1
Onishi, M	1
Ruiz, J	1
Case, D	1
Enevold, G	1
Rosdhal, R	1
Tatter, SB	1
Ellis, TL	1
McQuellon, RP	1
McMullen, KP	1
Stieber, VW	1
Shaw, EG	1
Lesser, GJ	1
Dhamne, M	1
Kang, SL	1
Ictech, SE	2
Liu, V	1
Loghin, M	1
de Groot, J	1
Alexander, BM	1
Wang, M	1
Fine, HA	2
Donahue, BA	1
Tremont, IW	1
Richards, RS	1
Kerlin, KJ	1
Hartford, AC	1
Curran, WJ	3
Mehta, MP	3
Lackner, H	1
Urban, C	1
Dornbusch, HJ	1
Schwinger, W	1
Kerbl, R	1
Sovinz, P	1
Maher, EA	1
Viscosi, E	1
Batchelor, T	1
Lakhani, N	1
Figg, WD	1
Purow, BW	1
Borkowf, CB	1
Hwu, WJ	4
Krown, SE	3
Menell, JH	2
Panageas, KS	3
Merrell, J	2
Lamb, LA	2
Williams, LJ	2
Quinn, CJ	1
Foster, T	1
Chapman, PB	2
Livingston, PO	2
Wolchok, JD	2
Houghton, AN	3
Chua, YJ	1
Steer, C	1
Yip, D	1
Chang, SM	2
Lamborn, KR	2
Malec, M	1
Larson, D	1
Wara, W	1
Sneed, P	1
Rabbitt, J	1
Page, M	1
Nicholas, MK	1
Prados, MD	2
Tan, DS	1
Evanson, J	1
Plowman, PN	1
Chew, SL	1
Fleming, FJ	1
Vytopil, M	1
Chaitow, J	1
Jones, HR	1
Darras, BT	1
Ryan, MM	1
Lis, E	2
Takano, S	1
Hada, M	1
Horiuchi, T	1
Son, MJ	1
Kim, JS	1
Kim, MH	1
Song, HS	1
Kim, JT	2
Kim, H	1
Shin, T	1
Jeon, HJ	1
Lee, DS	1
Park, SY	1
Kim, YJ	1
Kim, JH	1
Nam, DH	2
Lee, JI	1
Itasaka, S	1
Allegrini, G	1
Di Paolo, A	1
Cerri, E	1
Cupini, S	1
Amatori, F	1
Masi, G	1
Danesi, R	1
Marcucci, L	1
Bocci, G	1
Del Tacca, M	1
Falcone, A	1
Niedzwiecki, D	1
Hodgson, L	1
Haluska, FG	1
Tremont-Lukats, IW	1
Liu, TJ	1
Peterson, P	1
Cloughesy, TF	1
Greenberg, H	1
Abrey, LE	1
DeAngelis, LM	1
Gigas, DC	2
Muzikansky, A	2
O'Neill, A	1
Chen-Plotkin, AS	1
Weiss, SE	1
Levy, B	1
Bradshaw, J	1
Kracher, J	1
Laforme, A	2
Folkman, J	2
Kieran, M	2
Murphy, S	1
Davey, RA	1
Gu, XQ	1
Haywood, MC	1
McCann, LA	1
Mather, LE	1
Boyle, FM	2
Corn, BW	1
Moughan, J	1
Knisely, JP	2
Fox, SW	1
Chakravarti, A	2
Robins, HI	2
Brachman, DG	2
Henderson, RH	2
Movsas, B	2
Berkey, B	1
Yung, AW	1
Mahankali, S	1
Jackson, EF	1
Ritterhouse, MG	1
Henson, JW	1
Longtine, JA	1
Ligon, KL	1
Weaver, S	1
Burton, E	1
Prados, M	1
Cha, S	1
Knopp, EA	1
Johnson, G	1
Litt, A	1
Glass, J	1
Gruber, ML	1
Lu, S	1
Zagzag, D	1
Short, SC	1
Traish, D	1
Dowe, A	1
Hines, F	1
Gore, M	1
Brada, M	1
Avigdor, A	1
Raanani, P	1
Levi, I	1
Hardan, I	1
Ben-Bassat, I	1
Marx, GM	1
Pavlakis, N	1
McCowatt, S	1
Levi, JA	1
Bell, DR	1
Cook, R	1
Biggs, M	1
Little, N	1
Wheeler, HR	1
Mawrin, C	1
Aumann, V	1
Kirches, E	1
Schneider-Stock, R	1
Scherlach, C	1
Vogel, S	1
Mittler, U	1
Dietzmann, K	1
Krause, G	1
Weis, S	1
Raizer, J	1
Buelens, I	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme[NCT00112502]	Phase 2	178 participants (Actual)	Interventional	2005-09-30	Completed
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer[NCT06017284]	Phase 3	100 participants (Anticipated)	Interventional	2023-11-01	Recruiting
A Phase I/II Study of Temozolamide and Thalidomide in the Treatment of Advanced Melanoma[NCT00005815]	Phase 1/Phase 2	0 participants	Interventional	1999-12-31	Completed
Phase II Evaluation of Temozolomide (SCH52365) and Thalidomide for the Treatment of Recurrent and Progressive Glioblastoma Multiforme[NCT00006358]	Phase 2	44 participants (Actual)	Interventional	2000-06-13	Completed
Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278]		60 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Phase II Study Of Temozolomide, Thalidomide And Celecoxib In Patients With Newly Diagnosed Glioblastoma Multiforme In The Post-Radiation Setting[NCT00047294]	Phase 2	0 participants	Interventional	2001-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Celecoxib versus not Celecoxib analysis: We compared the median OS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.

Median Overall Survival (OS) Comparison of Doublet Versus Triplet Therapy

Intervention	months (Median)
Celecoxib: Arm III, Arm V, Arm VI and Arm VIII	20.2
No Celecoxib: Arm I, Arm II, Arm IV and Arm VII	17.1

Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median OS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.

Median Overall Survival (OS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms

Intervention	months (Median)
Doublet (2 Agents): Arm II, Arm III and Arm IV	17.0
Triplet (3 Agents): Arm V, Arm VI and Arm VII	20.1

Isotretinoin versus not Isotretinoin analysis: We compared the median OS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.

Median Overall Survival (OS) Comparison of Thalidomide Arms Versus no Thalidomide Arms

Intervention	months (Median)
Isotretinoin: Arm IV, Arm V, Arm VII and ARM VIII	17.1
No Isotretinoin: Arm I, Arm II, Arm III and ARM VI	19.9

Thalidomide versus not Thalidomide analysis: We compared the median OS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median OS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.

Median Progression-Free Survival (PFS) Comparison of Celecoxib Arms Versus no Celecoxib Arms

Intervention	months (Median)
Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII	18.3
No Thalidomide: Arm I, Arm III, Arm IV and Arm V	17.4

Celecoxib versus not Celecoxib analysis: We compared the median PFS outcome of participants in arms III, V, VI and VIII, versus participants in arms I, II, IV and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.

Median Progression-Free Survival (PFS) Comparison of Doublet Versus Triplet Therapy

Intervention	months (Median)
Celecoxib: Arm III, Arm V, Arm VI and Arm VIII	8.3
No Celecoxib: Arm I, Arm II, Arm IV and Arm VII	7.4

Doublet (2 agents) versus Triplet (3 agents) therapy analysis: We compared the median PFS outcome of participants in arms II, III, IV, versus participants in arms V, VI and VII. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.

Median Progression-Free Survival (PFS) Comparison of Isotretinoin Arms Versus no Isotretinoin Arms

Intervention	months (Median)
Doublet (2 Agents): Arm II, Arm III and Arm IV	8.3
Triplet (3 Agents): Arm V, Arm VI and Arm VII	8.2

Isotretinoin versus not Isotretinoin analysis: We compared the median PFS outcome of participants in arms IV, V, VII and VIII, versus participants in arms I, II, III and VI. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.

Median Progression-Free Survival (PFS) Comparison of Thalidomide Arms Versus no Thalidomide Arms

Intervention	months (Median)
Isotretinoin: Arm IV, Arm V, Arm VII and Arm VIII	6.6
No Isotretinoin: Arm I, Arm II, Arm III and Arm VI	9.1

Thalidomide versus not Thalidomide analysis: Comparison of median PFS outcome of participants in arms II, VI, VII and VIII, versus participants in arms I, III, IV and V. Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up, up to one year (12 study cycles).

Median Progression-Free Survival (PFS) of Individual Arms

Intervention	months (Median)
Thalidomide: Arm II, Arm VI, Arm VII and Arm VIII	7.6
No Thalidomide: Arm I, Arm III, Arm IV and Arm V	8.7

Median PFS was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 2 cycles (1 cycle = 28 days) from randomization until progression of disease, death or last follow-up.

Overall Survival of Individual Arms

Intervention	months (Median)
Arm I: TMZ	10.5
Arm II: TMZ + Thalidomide	7.7
Arm III: TMZ + Celecoxib	13.4
Arm IV: TMZ + Isotretinoin	6.5
Arm V: TMZ + Isotretinoin + Celecoxib	11.6
Arm VI: TMZ + Thalidomide + Celecoxib	7.9
Arm VII: TMZ + Thalidomide + Isotretinoin	6.2
Arm VIII: TMZ + Thalidomide + Isotretinoin + Celecoxib	5.8

Overall Survival (OS) was estimated using the Kaplan-Meier method from time of randomization to time of progression, death, or last follow-up. Progression defined as 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). (NCT00112502)
Timeframe: Every 3 months from randomization until progression of disease, death or last follow-up.

Article	Year
[Radiotherapy plus concomitant systemic therapies for patients with brain metastases from breast cancer]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blood-Brain Barri	2014
Adhesion molecules and the extracellular matrix as drug targets for glioma. Brain tumor pathology, 2016, Volume: 33, Issue:2 Topics: Angiogenesis Inhibitors; Antibodies; Brain Neoplasms; Cell Adhesion Molecules; Disease Progression;	2016
Angiogenesis and invasion in glioma. Brain tumor pathology, 2011, Volume: 28, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz	2011
Recent advances in management of small-cell lung cancer. Cancer treatment reviews, 2004, Volume: 30, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz	2004
[Anti-angiogenesis treatment for brain tumors--present and future]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr	2005
New chemotherapy options for the treatment of malignant gliomas. Current opinion in oncology, 1999, Volume: 11, Issue:3 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine;	1999

Article	Year
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro-oncology, 2015, Volume: 17, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cele	2015
A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. International journal of radiation oncology, biology, physics, 2009, Jan-01, Volume: 73, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dose-Response Relati	2009
A phase II study of thalidomide in patients with brain metastases from malignant melanoma. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:8 Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; F	2008
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer, 2008, Oct-15, Volume: 113, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Com	2008
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. Journal of neuro-oncology, 2012, Volume: 106, Issue:3 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; G	2012
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer, 2012, Jul-15, Volume: 118, Issue:14 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival;	2012
A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). Journal of neuro-oncology, 2013, Volume: 111, Issue:1 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Brain Neoplasms; Chemoradiotherapy; Female; Follow-Up St	2013
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-15, Volume: 21, Issue:12 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm	2003
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2003
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2003
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2003
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2003
Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. International journal of radiation oncology, biology, physics, 2004, Oct-01, Volume: 60, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che	2004
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer, 2005, Jun-15, Volume: 103, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2005
Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:5 Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy	2006
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). Cancer, 2006, Oct-15, Volume: 107, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2006
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of neuro-oncology, 2007, Volume: 81, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac	2007
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncology, 2007, Volume: 9, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm	2007
Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118. International journal of radiation oncology, biology, physics, 2008, May-01, Volume: 71, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Cognition; Cognition D	2008
A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). International journal of radiation oncology, biology, physics, 2008, May-01, Volume: 71, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Brain Neoplasms; Cognition Disorders; Combi	2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-oncology, 2008, Volume: 10, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Disease-	2008
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-oncology, 2008, Volume: 10, Issue:3 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm	2008
Thalidomide as an anti-angiogenic agent in relapsed gliomas. Journal of neuro-oncology, 2001, Volume: 51, Issue:1 Topics: Adult; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Glioma; Humans; Middle Aged; N	2001
Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. Journal of neuro-oncology, 2001, Volume: 54, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Endothelial Growth Factors	2001

Article	Year
Recurrent or progressive pediatric brain tumors: population pharmacokinetics and exposure-response analysis of pomalidomide. Pediatric research, 2021, Volume: 90, Issue:4 Topics: Adolescent; Antineoplastic Agents, Immunological; Brain Neoplasms; Child; Disease Progression; Dose-	2021
Metastatic Intracerebral Plasmacytoma Treated with Radiation and Thalidomide, Dexamethasone with Cyclophosphamide Chemotherapy. World neurosurgery, 2017, Volume: 103 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cranial Irradiation; Cyclophosphami	2017
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro-oncology, 2019, 12-17, Volume: 21, Issue:12 Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell	2019
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule]. Magyar onkologia, 2013, Volume: 57, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera	2013
Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:3 Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Disease Mode	2014
The successful treatment of a recurrent intracranial, dural-based plasmacytoma with lenalidomide. Journal of neuro-oncology, 2014, Volume: 119, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Brain Neoplasms; Female; Humans; Lenalidomide; Neoplasm Recurrence, L	2014
Factorial clinical trials: a new approach to phase II neuro-oncology studies. Neuro-oncology, 2015, Volume: 17, Issue:2 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Isotr	2015
17P deleted multiple myeloma presenting with intracranial disease: durable remission after tailored management. Hematological oncology, 2016, Volume: 34, Issue:3 Topics: Autografts; Bortezomib; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 17; Consolida	2016
Inhibition of 13-cis retinoic acid-induced gene expression of reactive-resistance genes by thalidomide in glioblastoma tumours in vivo. Oncotarget, 2015, Oct-06, Volume: 6, Issue:30 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Pro	2015
FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget, 2015, Dec-29, Volume: 6, Issue:42 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Area Under Curve; Astrocytes; Biom	2015
Mutations in STN1 cause Coats plus syndrome and are associated with genomic and telomere defects. The Journal of experimental medicine, 2016, 07-25, Volume: 213, Issue:8 Topics: Animals; Ataxia; Brain Neoplasms; Calcinosis; Central Nervous System Cysts; Disease Models, Animal;	2016
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. Journal of neurosurgery. Pediatrics, 2008, Volume: 2, Issue:2 Topics: Angiogenesis Inhibitors; Brain Neoplasms; Female; Hemangioma, Capillary; Humans; Infant, Newborn; Th	2008
The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma. Molecular cancer therapeutics, 2008, Volume: 7, Issue:8 Topics: Angiogenesis Inhibitors; Brain Neoplasms; Fibroblast Growth Factor 2; Glioma; Guanine; Humans; Promo	2008
Thalidomide in small cell lung cancer: wrong drug or wrong disease? Journal of the National Cancer Institute, 2009, Aug-05, Volume: 101, Issue:15 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Ne	2009
Brain amyloidoma with cerebral hemorrhage. The Journal of the American Osteopathic Association, 2009, Volume: 109, Issue:7 Topics: Amyloidosis; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhag	2009
Glioblastoma multiforme in a patient with chronic granulomatous disease treated with subtotal resection, radiation, and thalidomide: case report of a long-term survivor. Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:12 Topics: Adolescent; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Diagnosis, Differential; Female;	2009
Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease. Journal of neuro-oncology, 2010, Volume: 97, Issue:2 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Female; Hemangioendotheliom	2010
Interferon alfa-2a in recurrent metastatic hemangiopericytoma. Medical and pediatric oncology, 2003, Volume: 40, Issue:3 Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;	2003
Post-radiation inflammatory reaction controlled with thalidomide and rofecoxib. Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:8 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Edema; Brain Neoplasms; Female; Hemangioblasto	2004
Thalidomide neuropathy in childhood. Neuromuscular disorders : NMD, 2005, Volume: 15, Issue:2 Topics: Action Potentials; Adolescent; Brain Neoplasms; Child; Crohn Disease; Disease Progression; Electromy	2005
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. No shinkei geka. Neurological surgery, 2005, Volume: 33, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu	2005
Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model. International journal of oncology, 2006, Volume: 28, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cel	2006
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. Oncology reports, 2006, Volume: 15, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality	2006
Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model. Journal of neuro-oncology, 2007, Volume: 85, Issue:2 Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combin	2007
Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR. American journal of neuroradiology, 2000, Volume: 21, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Echo-Plan	2000
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. Leukemia & lymphoma, 2001, Volume: 42, Issue:4 Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl	2001
Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide. Journal of neuro-oncology, 2001, Volume: 55, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Diagnosis, Diff	2001
Treatment of metastatic melanoma in the brain with temozolomide and thalidomide. The Lancet. Oncology, 2001, Volume: 2, Issue:10 Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Dru	2001
[Treatment of a 2nd degree astrocytoma with thalidomide (N-phthalylglutamic acid amide]. Arzneimittel-Forschung, 1967, Volume: 17, Issue:5 Topics: Astrocytoma; Brain Neoplasms; Child; Humans; Male; Thalidomide	1967

thalidomide and Benign Neoplasms, Brain